Nicholas Stern Email

Chief Financial Officer . Vicebio

Current Roles

Employees:
24
Revenue:
$3.7M
About
Vicebio is a clinical-stage biopharmaceutical company developing transformative multi-pathogen vaccines for respiratory viral infections.\nAt the core of our work is Vicebio’s groundbreaking Molecular Clamp Technology, which locks viral proteins in their optimal conformation. This innovation enables our vaccines to deliver a unique combination of broad protection, ready-to-use administration, and convenient manufacturing.\nOur lead program is a best-in-class multivalent vaccine targeting five respiratory diseases, positioning Vicebio as a leader in multipathogen respiratory vaccines.
Vicebio Address

null, null
United States
Vicebio Email